Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran

Sepideh Paybast a, Seyed Amir Hejazi b, Payam Molavi c, Mohammad Amin Habibi d, Abdorreza Naser Moghadasi a,*

a Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran
b Associate Professor, Neuroscience Research Center, Qom University of Medical Sciences and Health, Qom, Iran
c Neurology Resident, Neuroscience Research center and Neurology Department, Beheshti Hospital, Qom University of Medical Sciences and Health, Qom, Iran
d Iranian tissue bank and research center, Gene, Cell and Tissue Institute, Tehran University of Medical Sciences and Health services, Tehran, Iran

ARTICLE INFO

Keywords: Multiple sclerosis
COVID-19
Vaccination
EDSS
Relapse

ABSTRACT

Background: In the current COVID-19 pandemic, Multiple Sclerosis (MS) patients represent a population of particular interest as they might be at higher risk of COVID-19 infection and its complications. The present study aimed to investigate a one year follow up of patients with MS during the COVID-19 pandemic, in Qom province, Iran.

Methods: This study was performed at the MS Clinic of Beheshti Hospital from June 1, 2020 to November 1, 2021. 202 patients with a diagnosis of MS and negative self-reported history of COVID-19 at the beginning of the pandemic, were enrolled. First, the demographic characteristics of patients were collected. Second, the patients underwent serological testing for anti-SARS-CoV-2 IgG antibodies. Then, a year later, they were reevaluated and asked about the occurrence of clinical relapse leading to hospitalization, disease progression, DMT profile, COVID-19 vaccination, and history of COVID-19 infection. We considered six weeks after COVID-19 regarding relapse occurrence. Eventually, statistical analysis was carried out by using SPSS 26.0

Results: Of 202 patients, 26 patients (12.87%) had initially a positive index antibody result. During the follow-up periods, 25 patients (12.37%) were infected with COVID-19 which was mainly mild (74.8%), and significantly lower than general population. 118 patients (58.41%) were vaccinated for COVID-19 which reduced the risk of COVID-19 development ($P < 0.001$). Except a case of myelitis associated with vaccination, no serious adverse event was reported. Additionally, only one patient developed MS relapse following COVID-19 infection. Except clinical relapse ($P = 0.001$), other demographic and MS characteristics, and DMT type were not associated with COVID-19. In terms of MS course, 12 patients (5.94%) discontinued their DMTs regardless of the DMT adverse events or treatment failure. 41 patients (20.3%) experienced a clinical relapse, of whom 12 were escalated to a second line DMT. Further, 27 patients (13.4%) noted a history of worsening disability which mainly occurred after COVID-19 infection.

Conclusion: The present study showed a significant lower incidence of COVID-19 infection in MS patients. Except for clinical relapse, other demographic and MS characteristics, and DMT type were not associated with COVID-19 infection. In addition, COVID-19 vaccination reduced the risk of COVID-19 development, and the prognosis was favorable in the majority of MS patients.

1. Introduction

In December 2019, a cluster of unexplained pneumonia in Wuhan, China, penetrated borders and became a global pandemic. The current pandemic and the numerous unexplained issues regarding the post-pandemic phase, make it more difficult to manage individuals who require immunosuppressive drugs. A large number of studies have shown that a high level of innate immunity, along with a deficiency in adaptive immunity, may worsen the COVID-19 infection, and the production of a significant variety of inflammatory cytokines may result in an adverse prognosis (Fauci et al., 2020; Ge et al., 14).

Multiple sclerosis (MS) is an immune-mediated central nervous...
system (CNS) disease that necessitates immunosuppressive or immuno-modulatory disease-modifying therapy (DMTs). Up to 70% of MS patients are managed with DMTs, which affect the immune response and may enhance the risk of infection (Koch-Henriksen and Magyari, 2021). Previous studies have shown a higher rate of respiratory tract infections in MS patients compared to general population, which rises with age, and degree of disability, especially in male sex. Notably, immunosuppressive DMTs as B cell therapies are more likely to be associated with severe infection as SARS CoV-2 infection and lower response to COVID-19 vaccination (Wijnands et al., 2017; Mohn et al., 2020; Grebencucova and Pruitt, 2017). Moreover, while MS is often thought to be a disease hampering young people, ageing patients with MS are increasing worldwide, who might be at higher risk of severe morbidity and death from COVID-19 (Mindén et al., 2020).

Considering the chronicity of MS, the importance of rehabilitation therapy which might be limited during the current pandemic, the long-term consequences of DMTs, and the challenges in DMTs initiation and continuation on one hand, and psychological burden of COVID-19 on the other, along with the possible complications of COVID-19 vaccination which all might increase the risk of MS relapse, in this cross-sectional study, we aimed to evaluate a one-year follow-up of patients with MS, in Qom province, Iran, to investigate the change of MS course in COVID-19 pandemic, and determine the COVID-19 occurrence according to the clinical profile of patients and different DMTs usage.

2. Material and methods

2.1. Study designs

This cross-sectional study was conducted at the MS Clinic of Qom province, Iran, from June 1, 2020 to November 1, 2021. The initial assessment was performed in a two-month period from June 1, 2020 to August 1, 2020. The second evaluation was performed in a similar period from August 1, 2021 to September 1, 2021.

The study received approval from the ethics committee of Qom University of Medical Sciences and Health (ethic code: IR.MUQ.REC.1400.102). Additionally, all patients fulfilled the informed consents prior to their participation in the study.

2.2. Study population

Patients were recruited from the MS clinic of Beheshti hospital, Qom, Iran. Eligible participants were selected according to inclusion criteria: patients with a diagnosis of MS based on McDonald Criteria 2017 and age over 18 years.

Patients with a self-reported history of COVID-19 prior to enrollment, patients who attempted to conceive, and those who were pregnant or in the postpartum period were excluded. Eventually, 202 patients met the eligibility criteria.

2.3. Interventions and data collection

First, in a face-to-face interviews with patients, a questionnaire of demographic characteristics consisted of age, gender, type of MS, DMTs use, Expanded Disability Severity Scale score (EDSS), and comorbidities was fulfilled. EDSS was assessed by the neurology resident, who was participated in the study.

Second, all patients underwent serological testing for anti-SARS-CoV-2 IgG antibodies. Then, a year later, the patients were reassessed. In the next visit, the clinical data including of history of clinical relapse leading to hospitalization, disease progression, DMT profile, COVID-19 vaccination, and history of COVID-19 infection were collected.

COVID-19 infection was confirmed based on a positive nasopharyngeal Polymerase chain reaction (PCR) test for SARS-CoV-2. Additionally, given the China’s National Health Commission, the severity of COVID-19 was classified as mild, moderate, and severe.

MS relapse was defined as a monophasic clinical episode with objective findings typical of MS, which was developed acutely or sub-acutely, with a duration of at least 24 h (Repovic, 2019). We considered six weeks as the period attributed to MS relapse in association with COVID-19 infection or vaccination.

2.4. Statistical analysis

Statistical analysis was carried out by using SPSS 26.0 (SPSS Inc, Chicago, IL) software. Data were expressed as mean ± SD for quantitative variables and counts (%) for categorical variables. One-sample Kolmogorov-Smirnov test, Chi-Square test, and Whitney-Mann statistical tests were used for data analysis, and multivariable regression model was used to evaluate the relation between DMT type and COVID-19 severity. The significance difference was considered $P < 0.05$.

3. Results

As June 1, 2020 to November 1, 2021, a total of 202 MS patients were included. One hundred and sixty-four patients (81.2%) were female, with a mean (SD) age of 37.52 ± 8.95 years. Approximately, 25.61% patients had one or more comorbidity, of that hypothyroidism was most frequently reported.

The results revealed that, the majority of patients (77.7%) had EDSS score < 2 with a mean score of 1.76 on a scale from 0 to 8. Relapse remitting MS (RRMS) was found as the most frequent MS type in all patients (71.78%). After a year, 27 patients (13.4%) noted a history of worsening disability, particularly after COVID-19 infection. However, this association was not considered to be significant ($P = 0.719$).

At the beginning of the study, 94.55% of the patients received DMTs, with IFN-β1a ($n = 66, 34.55%$) and anti-CD20 ($n = 47, 24.60%$) being the most frequently prescribed medications. However, in the following, 12 patients (5.94%) discontinued their DMTs regardless of the DMT adverse events or treatment failure, of whom 10 were receiving interferons, one was receiving glatiramer acetate, and one was taking dimethyl fumarate (DMF). Moreover, 41 patients (20.3%) experienced a clinical relapse which was mainly treated with methylprednisolone 1 gr/ d for 3–5 consecutive days. only one rituximab-treated RRMS patient experienced myelitis in the course of COVID-19 infection which was managed with therapeutic plasma exchange (TPE) for 5 sessions (alternate days). One standard TPE session was 2.5 plasma volume exchange using 5% albumin as a replacement fluid. The relapses were not significantly associated with COVID-19 infection ($P = 0.604$). Contrariwise, a statistical significance was demonstrated between relapse and COVID-19 vaccination ($P = 0.02$).

In terms of DMT adjustment, 12 patients with clinical relapse were escalated to a second line DMT, four of them to rituximab. Further, the rituximab was infused in an extended interval of 9–12 months in four patients.

Based on the results, a total of 26 patients (12.87%) showed seropositive for SARS CoV-2 IgG at the beginning of the study. Within one year, 25 patients (12.37%) developed COVID-19 which was considered to be mild in 74.8%. No one experienced recurrence of COVID-19 or persistent viral shedding. We also did not demonstrate a significant association between prior seropositive SARS CoV-2 status and future COVID-19 ($P = 0.24$).

As shown in Table 1, there was no significant association between demographic characteristics and COVID-19 ($P > 0.05$). In terms of MS characteristics, neither MS type ($P = 0.306$) nor EDSS score ($P = 0.319$) was associated with COVID-19. Conversely, a significant relationship was shown between clinical relapse and COVID-19 infection ($P = 0.001$).

In parallel, there was a significant correlation between the change of DMTs (escalation therapy) and the incidence of COVID-19 ($P = 0.001$). However, escalation to a particular type of DMT as rituximab was not associated with COVID-19 ($P = 0.712$).

Table 2 shows the medication history of patients after 12 months in...
Table 1
The baseline clinical characteristics of MS patients.

| Variable                  | COVID-19 infection | ψ value |
|---------------------------|--------------------|---------|
|                           | Negative         | Positive|         |
| Gender                    | Female (%)        | 144     | 20 (9.9%)| 0.698 |
|                           | Male (%)          | 32      | 5 (2.47%)|       |
| Age (mean ± SD)           | 38.09 ± 10.44     | 37.45 ± | 0.095 |
| MS course                 | MS (%)            | 8 (3.96%)| 1 (0.49%)| 0.306 |
|                           | CIS (%)           | 4 (1.98%)| 1 (0.49%)|       |
|                           | Primary-progressive (%) | 39 | 4 (1.98%)|       |
|                           | Secondary progressive (%) | 126 | 19 (0.49) |
| EDSS (mean)               | 1.76 ± 1.65       | 1.77 ± 1.52 | 0.319 |
| Comorbidity               | Negative (0.90%)  | 19 (6.54%) | 0.652 |
|                           | Hydrophyroidium   | 19 (9.40%)| 6 (2.97%)|       |
|                           | Hypertension      | 10 (4.95%)| 0 (0.00%)|       |
|                           | Diabetes mellitus | 8 (3.96%)| 0 (0.00%)|       |
|                           | Others            | 6 (2.97%)| 0 (0.00%)|       |
|                           | Positive (%)      | 2 (0.99%)| 0 (0.00%)|       |
| SARS-CoV 2 IgG level      | Negative (10.89%) | 155 (76.73%) | 21 (10.39%) | 0.24 |

MS: multiple sclerosis; CIS: clinically isolated syndrome; RRMS: relapse remitting multiple sclerosis; PPMS: primary progressive multiple sclerosis; EDSS: Expanded Disability Status Scale.

Table 2
The DMT medication of MS patients after 12 months and association between COVID-19 infection and DMT category.

| COVID-19 infection | Disease modifying treatment (DMT) | ψ value |
|--------------------|-----------------------------------|---------|
| Positive (n = 25)  | INF β 1a IM injection 5 (2.79%)  | 1 (0.55%)| 2 (1.11%)| 0 (0%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)| 0.190 |
| Negative (n = 177) | INF β 1a SC injection 5 (2.79%)  | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | INF β 1b SC injection 5 (2.79%)  | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Glatiramer acetate 5 (2.79%)      | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | DMF 5 (2.79%)                     | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Teriflunomide 5 (2.79%)           | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Fingolimod 5 (2.79%)              | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Natalizumab 5 (2.79%)             | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | No DMT 5 (2.79%)                  | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Rituximab 5 (2.79%)               | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |
|                   | Azathioprine 5 (2.79%)            | 1 (0.55%)| 2 (1.11%)| 0 (0.00%)| 3 (1.67) | 5 (2.79%)| 1 (0.55%)|       |

MS: multiple sclerosis; CIS: clinically isolated syndrome; RRMS: relapse remitting multiple sclerosis; PPMS: primary progressive multiple sclerosis; EDSS: Expanded Disability Status Scale.

4. Discussion

4.1. COVID-19 infection

In the present study, an 11.8% seroprevalence of COVID-19 was demonstrated in MS population at the beginning, which was much higher than the officially confirmed cases. The results were lower than a report in Iran on 8902 participants from the general population across 17 provinces, which revealed a total 17.1% seroprevalence of COVID-19 with a greater prevalence in Qom province (58.5%) (Poustchi et al., 2021). However, amid the COVID-19 pandemic, regardless of the nationwide increasing trend of COVID-19 prevalence and mortality in Iran (Hazbavi et al., 2021), only 12.3% of MS patients developed COVID-19 which was significantly lower than general population. Moreover, the majority of MS patients (74.8%) developed mild COVID-19, and no death was reported. The results also did not reveal a significant association between prior seropositivity of SARS-CoV-2 and risk of later COVID-19.

Given the autoimmune nature of MS and DMT treatment, which in most part, target the adaptive rather than the innate immune system, MS patients are theoretically more likely to succumb to serious infection, which raises concerns about the outcome of COVID-19 (Vishnevskys and Levy, 2020). However, COVID-19 incidence was lower in our patients. This might be related to different factors. The results showed that 58.41% of patients received two doses of Sinopharm vaccine. Further, a substantial number of our patients were female and young with no or few comorbidities. They were also more likely to adhere to strict quarantine and social distance. Also, potentially the reduced mobility in those with greater disability may make them less likely to be out in public areas where exposure might occur, even despite there being no difference in mean EDSS between COVID groups. Finally, the majority of patients continued their conventional treatment (93.71%), of which interferon-β were the most common (37.98%). Previous studies have shown the down regulatory effects of interferon-β on both pro- and anti-inflammatory cytokines which might inhibit SARS-CoV2 and attenuate the symptoms of COVID-19 (Zheng et al., 2020; Berger et al., 2020; McNab et al., 2015).

A large number of studies have investigated the risk factors of COVID-19, of which age, gender, and comorbidities have been considered as the main factors. However, there are conflicting results regarding the role of MS type and EDSS in the occurrence of COVID-19 (Saeed et al., 2021). Our data indicated that except for recent clinical relapse (P = 0.001), other demographic and MS characteristics (P > 0.05) did not remain independent factors for COVID-19. These results might be related to the relatively younger age of our patients with low frequency of individual comorbidities. Furthermore, patients with more benign course of MS and COVID-19 were more likely to participate in the study, which all resulted in a confounding bias. On the other hand, a negative association of clinical relapse and COVID-19 might be related to the corticosteroids therapy, as some guidelines have recommended to avoid or prescribe corticosteroids at the lowest possible dose, especially in cases of mild relapses (Dhamija et al., 2021). However, a report in our center did not reveal the increased risk of COVID-19 following pulse steroid therapy in MS patients (Naser Moghadasi et al., 2021). Moreover, the variable interval of pulse therapy and onset of COVID-19 makes this relationship unlikely.

In terms of DMT type, it is noteworthy that, a particular attention has been given to the DMTs in the COVID-19 era. While, prior studies revealed no apparent increase in the risk of COVID-19 with DMT type, later reports highlighted the possibly increased risk of infection and decreased immune response of COVID-19 vaccination for B cell-depleting agents (Zheng et al., 2020; Berger et al., 2020; Baker et al., 2020; Yamout et al., 2021; Zrzavy et al., 2021). The present study,
did not demonstrate a significant association between DMT type and risk of COVID-19 or the severity of COVID-19. We assume, our results might be related to the small sample size of the study, and specifically the small number of patients with severe COVID-19 leading to a selection bias. Further, a relatively low prevalence of rituximab administration, extended intervals of rituximab infusion, and lack of ocrelizumab administration might have played a role in improper interpretation.

4.2. MS course

In the current study, only one of the RRMS patients (4%) experienced a clinical relapse following COVID-19 infection, and except for a report of MS relapse (0.84%) following the first dose of Sinopharm, the post-vaccination adverse events were mild and comparable to previous reports (Achiron et al., 2021). However, an increased risk of relapse associated with COVID-19 vaccination was contrary to other reports, ranging from 0.9% in an Iranian report to 2.1% following the second dose of BNT162b2 COVID-19 vaccine in Israel (Ali Sahraian et al., 2021; Barzegar et al., 2021a).

Notably, while other types of coronaviruses have been reported to be related with demyelinating diseases, little association has been shown between COVID-19 infection and MS exacerbation or even MS manifestation. Similarly, the same is true of COVID-19 vaccination (Montalvan et al., 2020). The recently reports of a case of clinically isolated syndrome (CIS) and two cases of MS initiation with prior COVID-19 infection, and five cases of initial manifestation of MS associated with COVID-19 vaccine exposure, have alarmed such considerations (Domingues et al., 2020; Palao et al., 2020; Moore et al., 2021; Fujimori et al., 2021). In addition, reports of COVID-19 infection as a trigger of relapse in MS patients, have highlighted this association (Barzegar et al., 2021b; Michelema et al., 2021).

In terms of MS course, 12 patients (5.94%) discontinued their DMTs regardless of the DMT side effects or escalation therapy. 41 patients (20.3%) experienced a clinical relapse, of whom 12 were escalated to a second line DMT. Further, 27 patients (13.4%) had a history of slowly disability worsening, which mainly occurred after COIVD-19 infection. However, this association was not considered to be significant (\( P = 0.719 \)). To the best of our knowledge, there are no reports of MS progression in relation to COVID-19. Our preliminary results did not suggest the negative impact of COVID-19 on MS course. Still, more studies are needed to confirm our data.

4.3. Limitations and recommendations

To the best of knowledge, this is the first report in Iran evaluating a one year follow up of MS patients with a baseline COVID-19 serostatus. However, our work has some limitations. First, patients with significant disability and progressive form of MS were less likely to participate in the study leading to a healthy bias. Second, the small sample size of COVID-19 cases and especially those with a severe course, along with small sample size of patients on immunosuppressive therapy as B cell depleting agents might have led to a high degree of uncertainty. Third, as we did not check the serostatus of COVID-19 at the end of the study, there was a possibility to miss asymptomatic, mild or atypical COVID-19 cases. Eventually, the present study is restricted to MS patients who could be on DMTs, excluding women who were pregnant or attempting to conceive. This is potentially a limitation in terms of general disability, as it is possible that among all persons, including pregnant women or those attempting to conceive, the epidemiology of COVID-19 could differ.

Taking all considerations, as the COVID-19 pandemic is still ongoing, the demand for data on the impact of COVID-19 infection and COVID-19 vaccination on MS patients is crucial. Large multicenter studies are required to better understand the association of COVID-19 infection and vaccination with the demyelinating disorders to optimize the best practice in MS management.

5. Conclusion

The present study shows that the incidence of COVID-19 in MS
patients was similar to the general population, early in the pandemic. However, in the following, it significantly decreased, and COVID-19 vaccination decreased the risk of severe COVID-19 development. Except for clinical relapse, other demographic and MS characteristics, and DMT type were not associated with COVID-19. In addition, the majority of patients continued their conventional treatment, and the prognosis was generally favorable. Except for one case of MS relapse after vaccination and one case following COVID-19 infection, MS disease activity was not affected by COVID-19. Our results highlights the importance of comprehensive studies to elucidate the possible association of COVID-19 and MS, and provide a therapeutic guideline in MS population in COVID-19 era.

CRediT authorship contribution statement

Sepideh Paybast: Visualization, Funding acquisition, Methodology, Writing – original draft. Seyed Amir Hejazi: Visualization, Funding acquisition. Payam Molavi: Mohammad Amin Habibi: Formal analysis, Methodology, Writing – original draft. Abdorreza Naser Moghadasi: Writing – review & editing, Methodology, Writing – original draft, Formal analysis.

Acknowledgments

We thank the staff of the Department of Neurology for their kind help to manage the patients.

Funding

The authors have not declared a specific grant for this research from any funding agency.

References

Achiron, A., Dolev, M., Menascu, S., Zohar, D.-N., Dreyer-Alster, S., Miron, S., 2021. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult. Scler. J. 27 (6), 864-870 [Internet]May 15Available from: http://journal.sagepub.com/host/doi/10.1177/13524585211003476.
Ali Sahraian, M., Ghadiri, F., Azimi, A., 2021. Naser Moghadasi A. Adverse events of COVID-19 vaccine in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya slifka longitudinal multiple sclerosis study. NeuroRehabilitation 19 (1), 55-67 [Internet]Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968588.
Minden, S.L., Frankel, D., Hadden, L.S., Sinapius, K.P., Kreisl, J.N., 2004. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya slifka longitudinal multiple sclerosis study. NeuroRehabilitation 19 (1), 55-67 [Internet]Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968588.
Moore, L., Ghannam, M., Manousakis, G., 2021. A first presentation of multiple sclerosis with concurrent COVID-19 infection. eNeurologicalSci 22, 100299 [Internet]Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211034821002030.
Moha, N., Konen, F.F., Pul, R., Kleinshmitz, C., Prius, H., Witte, T., 2020. Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases. Clin. Neurol. Neurosurg. 203, 106563 [Internet]AprAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S1351925920304796.
Pouatchi, M., Darvishian, M., Mohammadzadeh R., Shayanrad, A., Delavari, A., Bahadorimofarad, A., 2021. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect. Dis. 21 (4), 473-481 [Internet]AprAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S147330992100085X.
Segura, T., 2020. Multiple sclerosis following SARS-CoV-2 infection. Mult. Scler. Relat. Disord. 45, 102377 [Internet]OctAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S235281812030092X.
Sekine, T., Konishi, K., Sugimoto, N., Furuse, T., Tsurumaru, N., 2021. Comparative study of the COVID-19 incidence pattern in Iran. Environ. Sci. Pollut. Res. 28 (11), 13605-13615 [Internet]Mar 1Available from: http://linkinghub.elsevier.com/retrieve/pii/S2211034821004922.
Rempel, P., 2019. Management of multiple sclerosis relapses. Contin. Lifelong Learn Neurol. 25 (3), 655-669 [Internet]JunAvailable from: http://journal.sagepub.com/host/doi/10.1177/135245852090001001.
Suh, Y., Kim, Y., Kim, C., Kim, Y., Lee, J., 2020. The epidemiology and severity of multiple sclerosis. Mult. Scler. Relat. Disord. 45, 102377 [Internet]OctAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S235281812030092X.
Vishnevetsky, A., Levy, M., 2020. Rethinking high-risk groups in COVID-19. Mult. Scler. Relat. Disord. 42, 102139 [Internet]JulAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S2211034821004251.
Wijnands, J.M., Kingwell, E., Zhu, F., Zhao, Y., Fisk, J.D., Evans, C., 2017. Infection-related health care utilization among people with and without multiple sclerosis. Mult. Scler. J. 23 (11), 1506-1516 [Internet]Oct 21Available from: http://journal.sagepub.com/host/doi/10.1177/1352458517742619.
Yamout, B.L., Zakaria, I., Imhasi, J., Al-Jumah, M., Zeineddine, M., Dahanleh, M., 2021. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult. Scler. Relat. Disord. 56, 103225 [Internet]NovAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S2352818120304922.
Zheng, Z., Peng, F., Xu, Z., Zhao, J., Liu, H., Peng, J., 2020. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J. Infect. 81 (2), e16-e25 [Internet]AugAvailable from: https://linkinghub.elsevier.com/retrieve/pii/S1550343X20339846.
Zrzavy, T., Wimmer, I., Rommer, P.S., Berger, T., 2021. Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur. J. Neurol. 28 (10), 3503-3516 [Internet]OctAvailable from: https://onlinelibrary.wiley.com/doi/10.1111/ene.15478.